More than two-thirds of cancer patients who were prescribed medical marijuana to combat pain are reportedly satisfied with the treatment, according to a comprehensive study conducted for the first time in Israel.

The study – conducted recently at Sheba Medical Center, Tel Hashomer, in conjunction with the Israel Cancer Association – involved 264 cancer patients who were treated with medical marijuana for a full year.

Some 61 percent of the respondents reported a significant improvement in their quality of life as a result of the medical marijuana, while 56 percent noted an improvement in their ability to manage pain. In general, 67 percent were in favor of the treatment, while 65 percent said they would recommend it to other patients.

The findings were presented earlier this month at an Israeli Oncologists Union conference in Eilat. The study was led by Dr. Ido Wolf, the director of oncology at the Sheba Cancer Center, with the assistance of researchers Yasmin Leshem, Damien Urbach, Adato Berliz, Tamar Ben Ephraim and Meital Gerty.

According to the study, the most common types of cancer for which medical marijuana is prescribed are lung cancer (21 percent ), breast cancer (12 percent ) and pancreatic cancer (10 percent ).

Researchers found that an average of 325 days passed between the time that patients were diagnosed with cancer and the time that they submitted permit requests to grow or possess medical marijuana. About 81 percent of those requests cited pain resulting from the illness. Some 8 percent of patients requested medical marijuana to combat nausea, while another 8 percent complained of weakness.

For more, go to Haaretz.com

This is a moment of great uncertainty. Here’s what you can do about it.

We hope you appreciated this article. Before you go, we’d like to ask you to please support the Forward’s independent Jewish news this Passover.

This is a moment of great uncertainty for the news media, for the Jewish people, and for our sacred democracy. It is a time of confusion and declining trust in public institutions. An era in which we need humans to report facts, conduct investigations that hold power to account, tell stories that matter and share honest discourse on all that divides us.

With no paywall or subscriptions, the Forward is entirely supported by readers like you. Every dollar you give this Passover is invested in the future of the Forward — and telling the American Jewish story fully and fairly.

The Forward doesn’t rely on funding from institutions like governments or your local Jewish federation. There are thousands of readers like you who give us $18 or $36 or $100 each month or year.

Don't just read the Forward - invest in it. Make a gift today.

Support our mission to tell the Jewish story fully and fairly.

Support Our Work